Hematopoiesis News

Hematopoiesis News is an online resource that provides updates on the latest research in the fields of hematopoiesis, blood, and bone marrow disorders.

Subscribe|Follow Us On

Phase I/II Study of High-Dose Palifermin for GVHD Prophylaxis in Patients Undergoing HLA-Matched Unrelated Donor HCT

May 20, 2025

[Blood] Researchers conducted a Phase I/II trial evaluating high-dose palifermin for preventing severe chronic GVHD in matched unrelated donor T cell replete peripheral-blood HCT following reduced-intensity conditioning.

Regulation of H3K4me3 Breadth and MYC Expression by the SETD1B Catalytic Domain in MLL-Rearranged Leukemia

May 20, 2025

[Leukemia] Researchers identified the modifier responsible for high histone H3 lysine 4 trimethylation (H3K4me3) modification in mixed-lineage leukemia-rearranged (MLL-r) leukemia and its downstream targets essential for the cell proliferation.

Phase II Study of Venetoclax Added to Bendamustine and Obinutuzumab in Patients with High-Risk Follicular Lymphoma As Front-Line Therapy: PrE0403

May 20, 2025

[Blood Cancer Journal] The Phase II PrE0403 study was designed to evaluate intermittent dosing of venetoclax combined with obinutuzumab and bendamustine in untreated follicular lymphoma subjects with high-risk features defined as a FLIPI-1 score of ≥3 and/or high tumor burden by GELF criteria.

Design Principles of Cell-State-Specific Enhancers in Hematopoiesis

May 20, 2025

[Cell] Investigators characterized 64,400 fully synthetic DNA sequences to bottom-up dissect design principles of cell-state-specific enhancers in the context of the differentiation of blood stem cells to seven myeloid lineages.

Novel, Potent, and Orally Bioavailable LSD1 Inhibitors Induce Fetal Hemoglobin Synthesis in a Sickle Cell Disease Mouse Model

May 20, 2025

[Blood] Researchers utilized structure-aided drug design to develop potent new reversible lysine-specific demethylase 1 inhibitors' (LSD1i's) leading to robust γ-globin expression in vitro.

Delineating Mpl-Dependent and -independent Phenotypes of Jak2 V617F- Positive MPNs In Vivo

May 20, 2025

[Blood] Scientists used a novel mouse model expressing Jak2 V617F under its endogenous promoter at the heterozygous state within a Mpl knock-out background.

Lactate Dehydrogenase A-Coupled NAD+ Regeneration Is Critical for Acute Myeloid Leukemia Cell Survival

May 20, 2025

[Cancer & Metabolism] Scientists demonstrated that AML cells critically depend on lactate dehydrogenase A (LDHA) to maintain an adequate NAD⁺/NADH balance in support of their abnormal glycolytic activity and biosynthetic demands, which cannot be compensated for by other cellular NAD⁺ recycling systems.

Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Different Non-T-Cell Depletion Protocols

May 20, 2025

[MedComm] The authors provide an analysis of immune reconstitution (IR) following haplo-HSCT with different protocols; it compares the clinical outcomes of various protocols, addresses the role of each immune cell subset in influencing outcomes and discusses emerging strategies aimed at improving IR.

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase I/II Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation...

May 20, 2025

[Aptose Biosciences, Inc.] Aptose Biosciences, Inc. announced that the Cohort Safety Review Committee monitoring Aptose’s Phase I/II TUSCANY trial of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine has approved escalating from 80 mg dose tuspetinib (TUS) to 120 mg dose TUS based on its favorable review of safety and efficacy data from patients in the first two cohorts of the trial.

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid Leukemias

May 15, 2025

[Clinical Cancer Research] The authors investigated the antileukemia efficacy of co-targeting FLT3 and MDM2 with quizartinib and milademetan in FLT3-internal tandem duplication AML cell lines, xenograft and patient-derived xenograft models, and a Phase I clinical trial.

Menin Inhibition with Revumenib for NPM1-Mutated Relapsed or Refractory Acute Myeloid Leukemia: The AUGMENT-101 Study

May 15, 2025

[Blood] Scientists presented results from patients with relapsed or refractory nucleophosmin 1-mutated AML enrolled in the Phase II portion of AUGMENT-101.

Novel, Potent, and Orally Bioavailable LSD1 Inhibitors Induce Fetal Hemoglobin Synthesis in a Sickle Cell Disease Mouse Model

May 15, 2025

[Blood] Investigators utilized structure-aided drug design to develop potent new reversible lysine-specific demethylase 1 (LSD1) inhibitors leading to robust γ-globin expression in vitro.

Hematopoiesis News curates the top publications and reviews covering the regulation, expression patterns, differentiation and characterization of hematopoietic stem cells, as well as blood and bone marrow disorders. We also feature the latest job postings and upcoming conferences in the hematopoiesis field.